The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

miRNA dysregulation of AGE/RAGE signaling in the context of MetS and its comorbidities seems significant but insufficiently studied. Even with a deductive approach, one cannot help but notice that ...